| Dr Paul Allen Brittain, MD | |
|
715 Dr Martin Luther King Jr Ave Ne Ste 102, Albuquerque, NM 87102 | |
| (505) 727-3040 | |
| (505) 727-9590 |
| Full Name | Dr Paul Allen Brittain |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 12 Years |
| Location | 715 Dr Martin Luther King Jr Ave Ne Ste 102, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184980989 | NPI | - | NPPES |
| 24158038 | Medicaid | NM |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lovelace Medical Center | Albuquerque, NM | Hospital |
| Lovelace Women's Hospital | Albuquerque, NM | Hospital |
| Lovelace Westside Hospital | Albuquerque, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Medical Associates, Llc | 7214831114 | 291 |
News Archive
Osteoarthritis (OA) is one of the most pressing health care challenges of our time, affecting 27 million Americans. In an effort to elucidate the latest information in diagnosis, treatment, research and prevention, Hospital for Special Surgery (HSS) will host an international Osteoarthritis Summit on June 17 and June 18.
Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient's unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).
It is time to discard the word euthanasia because it mixes ideas and values that confuses the debate about dying, states an editorial in CMAJ (Canadian Medical Association Journal)
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease
› Verified 8 days ago
| Entity Name | Southwest Medical Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164491072 PECOS PAC ID: 7214831114 Enrollment ID: O20031121000724 |
News Archive
Osteoarthritis (OA) is one of the most pressing health care challenges of our time, affecting 27 million Americans. In an effort to elucidate the latest information in diagnosis, treatment, research and prevention, Hospital for Special Surgery (HSS) will host an international Osteoarthritis Summit on June 17 and June 18.
Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient's unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).
It is time to discard the word euthanasia because it mixes ideas and values that confuses the debate about dying, states an editorial in CMAJ (Canadian Medical Association Journal)
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease
› Verified 8 days ago
| Entity Name | Lovelace Health System Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245798024 PECOS PAC ID: 9739099326 Enrollment ID: O20031210000397 |
News Archive
Osteoarthritis (OA) is one of the most pressing health care challenges of our time, affecting 27 million Americans. In an effort to elucidate the latest information in diagnosis, treatment, research and prevention, Hospital for Special Surgery (HSS) will host an international Osteoarthritis Summit on June 17 and June 18.
Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient's unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).
It is time to discard the word euthanasia because it mixes ideas and values that confuses the debate about dying, states an editorial in CMAJ (Canadian Medical Association Journal)
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul Allen Brittain, MD 715 Dr Martin Luther King Jr Ave Ne Ste 102, Albuquerque, NM 87102-3666 Ph: (505) 727-3040 | Dr Paul Allen Brittain, MD 715 Dr Martin Luther King Jr Ave Ne Ste 102, Albuquerque, NM 87102 Ph: (505) 727-3040 |
News Archive
Osteoarthritis (OA) is one of the most pressing health care challenges of our time, affecting 27 million Americans. In an effort to elucidate the latest information in diagnosis, treatment, research and prevention, Hospital for Special Surgery (HSS) will host an international Osteoarthritis Summit on June 17 and June 18.
Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient's unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).
It is time to discard the word euthanasia because it mixes ideas and values that confuses the debate about dying, states an editorial in CMAJ (Canadian Medical Association Journal)
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease
› Verified 8 days ago
Dr. Alberto Aguayo Rico, M.D, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 401 San Mateo Blvd Se, Albuquerque, NM 87108 Phone: 505-462-7333 Fax: 505-462-7440 | |
Peter Guido, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 4700 Jefferson St Ne, Ste 800, Albuquerque, NM 87109 Phone: 505-872-6000 Fax: 505-872-6003 | |
Kenneth A Bell, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2901 Transport St Se, Albuquerque, NM 87106 Phone: 505-262-7110 Fax: 505-262-7308 | |
Joseph F. Oser, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1501 San Pedro Dr Se, Albuquerque, NM 87108 Phone: 505-265-1711 | |
Dr. Stanley Zissman Berman, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 7416 Vista Del Arroyo Ave Ne, Albuquerque, NM 87109 Phone: 505-884-7270 | |
Huyentrang Vu, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Unm Hospital Internal Medicine, 2211 Lomas Blvd Ne, Albuquerque, NM 87131 Phone: 505-272-6225 | |
Tamara Goodman, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4901 Lang Ave Ne, Albuquerque, NM 87109 Phone: 505-842-8171 |